Abstract
Targeted delivery of functional nucleic acids (genes and oligonucleotides) to pulmonary endothelium may become a novel therapy for the treatment of various types of lung diseases. It may also provide a new research tool to study the functions and regulation of novel genes in pulmonary endothelium. Its success is largely dependent on the development of a vehicle that is capable of efficient pulmonary delivery with minimal toxicity. This review summarizes the recent progress that has been made in our laboratory along these research directions. Factors that affect pulmonary nucleic acids delivery are also discussed.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Administration, Inhalation
-
Animals
-
Antigens, Surface / drug effects
-
Cations / pharmacokinetics
-
Dependovirus / genetics
-
Drug Carriers / administration & dosage
-
Drug Carriers / pharmacokinetics
-
Drug Delivery Systems / methods*
-
Endothelial Cells / drug effects
-
Genetic Therapy / methods
-
Genetic Vectors / administration & dosage
-
Genetic Vectors / pharmacokinetics
-
Humans
-
Injections, Intravenous
-
Lipids / administration & dosage
-
Lipids / pharmacokinetics
-
Liposomes / administration & dosage
-
Liposomes / pharmacokinetics
-
Lung / blood supply*
-
Lung / cytology
-
Mice
-
Nucleic Acids / administration & dosage
-
Nucleic Acids / pharmacokinetics*
-
Nucleic Acids / therapeutic use
-
Oligonucleotides / administration & dosage
-
Oligonucleotides / pharmacokinetics
-
Oligonucleotides / therapeutic use
-
Peptides / administration & dosage
-
Peptides / pharmacokinetics
-
Polymers / pharmacokinetics
-
Pulmonary Circulation*
-
RNA, Small Interfering / administration & dosage
-
RNA, Small Interfering / pharmacokinetics
-
RNA, Small Interfering / therapeutic use
Substances
-
Antigens, Surface
-
Cations
-
Drug Carriers
-
Lipids
-
Liposomes
-
Nucleic Acids
-
Oligonucleotides
-
Peptides
-
Polymers
-
RNA, Small Interfering